ResMed (NYSE: RMD) reported Q3 EPS of $1.68, $0.09 better than the analyst estimate of $1.59. Revenue for the quarter came in at $1.12 billion versus the consensus estimate of $1.05 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.